PSGL-1, a specific ligand for P-, E- and L-selectin, was isolated from in vivo [3H]-glucosamine labeled HL- 60 cells by a combination of wheat germ agglutinin-agarose and P- or E-selectin-agarose chromatography. N- li...PSGL-1, a specific ligand for P-, E- and L-selectin, was isolated from in vivo [3H]-glucosamine labeled HL- 60 cells by a combination of wheat germ agglutinin-agarose and P- or E-selectin-agarose chromatography. N- linked oligosaccharides were released from the purified, denatured ligand molecule by peptide: N-glycosidase F treatment and, following separation by Sephacryl S-200 chromatography, partially characterized using lectin, ion-exchange and size-exclusion chromatography in combination with glycosidase digestions. The data obtained suggest that the N-glycans on PSGL-1 are predominantly core-fucosylated, multiatennary complex type structures with extended, poly- N- acetyllactosamine contaniing outer chains. A portion of the outer chains appears to be substituted with fucose indicating that the N-glycans, in addition to the O-glycans on PSGL-1, may be involved in selectin binding.展开更多
Glycoproteins from tumor cells isolated by Con A, PHAE and RCAI, were coupled to horse radish peroxidase and then used as reporters to evaluate the oligosaccharides change on serum glycoproteins in digestive tract dis...Glycoproteins from tumor cells isolated by Con A, PHAE and RCAI, were coupled to horse radish peroxidase and then used as reporters to evaluate the oligosaccharides change on serum glycoproteins in digestive tract diseases and individual healthy persons. A value 2 standard deviation above the mean of the healthy person group was considered positive. The results indicated that the positive rates of the oligosaccharides bound with Con A, PHA-E and RCAI were 51 % (61/119) . 70. 6% (84/119) , and 76. 4% (91/119) in patients with gastric cancer: 53. 3% (16/30),46. 7% ( 14/30) and 66. 7% (20/30) in esophageal cancers; 28. 5% (15/49), 49. 0% (24/49) and .46. 9% (23/49) in colorectal cancer; 78. 1% (25/ 32) ,81. 3% (26/32) and 31. 3% (10/32) in gallbladder tumors; 60. 4% (29/48), 54. 1% (26/48) and 39. 5% (19/48) in hepatocellular cancer. The positive rates among the patients with benign diseases were also found to be 12. 7% (16/126), 15. 5% (20/126) and 26. 2% (33/126). However, the expression of the oligosaccharide moieties recognized by WGA on the glycoprotein bound with Con A, was significantly lower in the serum of patients with tumors than in those with benign disease and in healthy individuals (P<0. 01 , P<0. 01).展开更多
文摘PSGL-1, a specific ligand for P-, E- and L-selectin, was isolated from in vivo [3H]-glucosamine labeled HL- 60 cells by a combination of wheat germ agglutinin-agarose and P- or E-selectin-agarose chromatography. N- linked oligosaccharides were released from the purified, denatured ligand molecule by peptide: N-glycosidase F treatment and, following separation by Sephacryl S-200 chromatography, partially characterized using lectin, ion-exchange and size-exclusion chromatography in combination with glycosidase digestions. The data obtained suggest that the N-glycans on PSGL-1 are predominantly core-fucosylated, multiatennary complex type structures with extended, poly- N- acetyllactosamine contaniing outer chains. A portion of the outer chains appears to be substituted with fucose indicating that the N-glycans, in addition to the O-glycans on PSGL-1, may be involved in selectin binding.
文摘Glycoproteins from tumor cells isolated by Con A, PHAE and RCAI, were coupled to horse radish peroxidase and then used as reporters to evaluate the oligosaccharides change on serum glycoproteins in digestive tract diseases and individual healthy persons. A value 2 standard deviation above the mean of the healthy person group was considered positive. The results indicated that the positive rates of the oligosaccharides bound with Con A, PHA-E and RCAI were 51 % (61/119) . 70. 6% (84/119) , and 76. 4% (91/119) in patients with gastric cancer: 53. 3% (16/30),46. 7% ( 14/30) and 66. 7% (20/30) in esophageal cancers; 28. 5% (15/49), 49. 0% (24/49) and .46. 9% (23/49) in colorectal cancer; 78. 1% (25/ 32) ,81. 3% (26/32) and 31. 3% (10/32) in gallbladder tumors; 60. 4% (29/48), 54. 1% (26/48) and 39. 5% (19/48) in hepatocellular cancer. The positive rates among the patients with benign diseases were also found to be 12. 7% (16/126), 15. 5% (20/126) and 26. 2% (33/126). However, the expression of the oligosaccharide moieties recognized by WGA on the glycoprotein bound with Con A, was significantly lower in the serum of patients with tumors than in those with benign disease and in healthy individuals (P<0. 01 , P<0. 01).
